The October 25, 2012 NIH March-In Request for ritonavir is now more than one year old, and the NIH has not decided to grant a hearing or reject the petition.
More information about the March-In request is available here:
https://www.keionline.org/2012ritonavir
Continue Reading →
KEI has asked 21 persons following the TPP IPR negotiations, what they thought of four of the USTR negotiators, including:
- Ambassador and USTR head Michael Froman,
- TPP Chief negotiator Barbara Weisel
- Assistant USTR for Intellectual Property and Innovation Stanford McCoy, and
- Deputy Assistant USTR for Intellectual Property and Innovation Probir Mehta.
Continue Reading →
At the request of the European Union, Jamaica, Mexico and the United States of America, the topic of “Intellectual Property and Sports” was placed for discussion at the World Trade Organization’s (WTO) October 2013 session of the Council for TRIPS (TRIPS Council).
Continue Reading →
See also: /2012ritonavir
15 frequently asked questions about the 2012 ritonavir March-In petition
Q1. What is the Bayh-Dole Act?
The Bayh-Dole Act (or University and Small Business Patent Procedures Act) was originally enacted in 1980 as Public Law 96-517, and was amended in 1984 by Public Law 98-620. Among other things, the Bayh-Dole Act was designed to facilitate the patenting of U.S. government funded inventions by universities, other non-profit entities and businesses, and also:
Continue Reading →